Brief: U.S. FDA Lifts Partial Hold On Application For Lead Drug

IRulya Therapeutics

28/09/2023 22:53

Sept 28 (Reuters) - Quince Therapeutics Inc  QNCX.O :
    * U.S. FDA PARTIAL CLINICAL HOLD LIFTED ON IND FOR ERYDEL’S
LEAD
PHASE 3 ASSET ERYDEX FOR THE TREATMENT OF ATAXIA-TELANGIECTASIA
    * QUINCE THERAPEUTICS: LOOK FORWARD TO COMPLETING CLINICAL
AND
REGULATORY ACTIVITIES NECESSARY TO ADVANCE ERYDEX INTO PHASE 3
NEAT STUDY
    * QUINCE THERAPEUTICS: PATIENT ENROLLMENT FOR ERYDEX PHASE 3
NEAT
STUDY BEGINNING AS SOON AS Q2 OF 2024

Source text for Eikon:  ID:nBw9rDdfRa 
Further company coverage:  QNCX.O 

 ((Reuters.Briefs@thomsonreuters.com;))